An observational study in Cardiovascular Diseases and Vascular Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 5 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational
Background:
Diseases related to the immune system, blood clots, and blood vessels can affect every part of the body. These diseases are now known to be interrelated: People who have strokes, blood clots in their legs, or autoimmune disease, for example, are at greater risk of complications in the heart, brain, and other organs. Researchers want to learn more about how these diseases start, how they change over time, and how they affect different organs.
Objective:
To learn more about how inflammation and diseases of the blood vessels start and how they change over time.
Eligibility:
People aged 5 years and older with a disease related to blood clots, the immune system, or blood vessels. Healthy relatives of people with these diseases and unrelated healthy volunteers are also needed.
Design:
Participants will have a baseline visit: They will provide a medical history, physical exam and blood test. All other tests and procedures are optional; these may be spread over more than 1 day:
Tests of heart and lung function.
Fill in a family tree form.
Imaging scans
Treadmill or bike stress tests and a 6-minute walk test.
Tests of blood pressure and the flow of blood through vessels.
Photos of the face and body.
Eye exams, with photos taken of the retina.
Saliva and urine samples.
Biopsies (tissues samples) of the skin and fat.
Tests of thinking and mental function.
Evaluations by other medical specialists.
Participants may opt to return for repeat testing for up to 90 months (7.5 years).
Some visits may be done by telehealth.
Study Description:
Thrombotic vascular disorders remain the leading cause of morbidity and mortality in the United States. The proximate determinants of thrombosis, arterial, venous, and lymphatic vascular disorders and their treatments remains incompletely understood. In pursuit of improved vascular health, this disease discovery protocol will facilitate rapid initiation of new clinical and molecular phenotype-specific investigations to collect data and biospecimens on affected individuals, family members, and unrelated healthy controls. The data collected in this protocol will inform the design of future disease-specific investigational protocols.
Objectives:
Primary Objective:
To study the pathogenesis of patients affected with thrombotic, immune, vascular, and cardiovascular conditions including clinical, radiographic, immunological and genetic characteristics of the disease.
Secondary Objectives:
Endpoints:
This is a disease discovery protocol and there are no specific endpoints associated with this protocol.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,117 studies on the registry; 71 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 49 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with relevant immune, inflammation, thrombotic and/or vascular diseases and their relatives Healthy volunteers
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
In addition, the following cohort-specific inclusion criteria apply:
Affected Subjects:
-Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and/or discussion of medical history
Relatives of Affected Subjects:
-Being a relative of an affected subject
Unrelated Healthy Controls:
-In good general health as evidenced by medical history
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
-Any condition that in the opinion of the Investigator would warrant exclusion
Unrelated Healthy Controls:
Participants with relevant immune, inflammation, thrombotic and/or vascular diseases and their relatives
Healthy volunteers
This is a disease discovery protocol and there are no specific endpoints associated with this protocol.
Time frame: Study End
Plan to share: Yes — Deidentified data from IPD or aggregated data may be shared in publications for scientific data reporting and interpretation.
Supporting information: Study protocol, Icf
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Heart, Lung, and Blood Institute (NHLBI)